Treatment with avelumab
toxicity
ADVERSE EVENT
Patients receive a maximum of 3 cycles avelumab every 2 weeks, provided that toxicity is acceptable. Avelumab is supplied by Merck (CrossRef Funder ID: 10.13039/100009945), as part of an alliance between Merck and Pfizer. The first administration should be within 2–4 weeks after day 21 of the last cycle of chemotherapy. Prior to each cycle, blood and urine is examined. Avelumab is given intravenously in 1 h at a dosage of 800 mg. Pre-medication is mandatory and is performed as per manufacturer’s recommendation to mitigate infusion-related reactions. Adverse events related to immunotherapy are to be managed according to local guidelines. Dose reduction for toxicity management is not permitted. In case of persisting toxicity, the next cycle of avelumab administration may be omitted until toxicity is resolved or decreased to at least Grade 1 in severity according to the NCI-CTCAE criteria [